We identified a subset of cell lines with an ITGAV vulnerability and a differential sensitivity to cilengitide, an integrin inhibitor targeting ITGAV:ITGB3 and ITGAV:ITGB5. Next, we sought to ...

FF-10158 is under clinical development by Advanced Accelerator Applications and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for ...

This study provides important insights into postnatal lung development and the mechanisms underlying bronchopulmonary dysplasia (BPD), a condition with high morbidity and mortality in newborns.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Muscle injury induces expression of myokines ...

Conclusions: In a combination of proteome-wide MR and RNA sequencing analysis, ANGPTL4 and ITGAV were identified as the pivotal protein targets associated with the progression of CAVD.

It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling. For a complete ...

Department of Hepatobiliary and Pancreatic Surgery, Medical School of Nantong University, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China Research Center of Clinical Medicine ...

Figure 2. Featured Products including ITGAV, VCAM1, and N-Cadherin. Image Credit: Sino Biological Inc. Recombinant proteins, ELISA kits, and other products are available as additional offerings.

The α-v integrin (ITGAV) consists of a subset that shares a common α-v subunit. ITGAV always binds to five β subunits to form receptors for hyaline, cellular actin, fibronectin, fibrinogen, and ...